Company Filing History:
2 out of 155 
1 out of 1 
1 out of 60 
Years Active: 2013-2016
Title: The Innovative Contributions of Andreas Von Deimling
Introduction
Andreas Von Deimling, an accomplished inventor based in Schriesheim, Germany, has made significant strides in the fields of diagnostics and disease monitoring. With three patents to his name, he has developed cutting-edge methodologies and tools that enhance the understanding and detection of various health conditions, particularly in oncology and metabolic disorders.
Latest Patents
Von Deimling's most recent patents showcase his expertise in the detection of important biochemical markers. One notable patent involves the means and methods for determining (D)-2-hydroxyglutarate (D2HG) and (D)-2-hydroxyadipic acid. This innovative method utilizes a reagent mixture that includes a solvent, a distinguishable dye, an electron transfer agent, and specific enzymes alongside a cofactor. This process not only aids in the accurate detection of these metabolites in samples but also helps in diagnosing and monitoring (D)-2-hydroxyglutarate-associated diseases.
Another significant patent focuses on cancer diagnostics through the use of antibodies specifically binding to the BRAF V600E epitope. This invention presents a method for diagnosing cancer by analyzing samples for the binding of these antibodies, thus contributing valuable techniques to the field of cancer research and diagnostics.
Career Highlights
Andreas Von Deimling has collaborated with prominent institutions throughout his career, significantly impacting cancer research and diagnostics. He has held positions at the German Cancer Research Center (Deutsches Krebsforschungszentrum), the German Cancer Research Center Foundation of Public Law (Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts), and Ruprecht-Karls-Universität Heidelberg. His work at these organizations underscores his commitment to the advancement of medical science and technology.
Collaborations
Throughout his journey, Von Deimling has worked alongside esteemed colleagues such as Hanswalter Zentgraf and David Capper. These collaborations have not only enhanced his research capabilities but have also fostered an environment of innovation and teamwork in their respective fields.
Conclusion
Andreas Von Deimling represents the spirit of innovation in modern science. With his groundbreaking patents and collaborative achievements, he continues to influence the landscape of diagnostics, particularly in cancer detection and metabolic disease monitoring. His contributions are invaluable in the quest for more effective diagnostic tools that enhance patient care and outcomes in medical practice.